ABSTRACT
Objective No studies have yet evaluated whether light therapy or negative ion therapy can be used as maintenance treatment after acute treatment with antidepressants in patients with major depressive disorder. To address the importance of this question, we surveyed participants with depression to determine their knowledge and attitudes about light therapy and negative ion therapy, and their willingness to participate in a randomized clinical trial with these therapies substituting for antidepressants for maintenance treatment.
Methods Participants with a self-reported diagnosis of depression were recruited by email, newsletters, and social media to complete an online survey with questions about awareness and effectiveness of light therapy and negative ion therapy for depression. Vignettes describing the use of these therapies for maintenance treatment were presented with follow up questions about the ease of use and reasons for wanting (and not wanting) to use the therapies instead of antidepressants. Another vignette described a randomized study with these therapies followed by questions on whether participants would likely volunteer for the study. Chi-square tests were used to examine differences in responses between therapies.
Results A total of 221 participants completed the survey. Most of them were aware of both therapies, but more participants had heard of light therapy (95% compared to 62% for negative ion therapy, p<0.0001), had used light therapy (28% versus 16%, p<0.003), and regarded light therapy as effective (54% versus 37%, p<0.001). Both therapies were considered easy to use. The majority of participants (78%) thought that it was important to find non-medication therapies for maintenance treatment, and 77% responded that they would likely volunteer for a randomized study to determine efficacy of the two therapies for maintenance treatment.
Conclusion People with depression are generally aware of light therapy and negative ion therapy and believe they would be good therapies to substitute for antidepressants in maintenance treatment. These findings support the importance and feasibility for a randomized relapse prevention trial with light therapy and negative ion therapy in patients with depression.
Competing Interest Statement
IL, VWL, AD, and JKM have no disclosures. AS is Founder and Chief Executive Officer of SpeakBox, a digital technology company. EEM has received funding to support patient education initiatives from Otsuka. RWL has received honoraria for ad hoc speaking or advising/consulting, or received research funds, from Allergan, Asia-Pacific Economic Cooperation, BC Leading Edge Foundation, Canadian Institutes of Health Research, Canadian Network for Mood and Anxiety Treatments, Healthy Minds Canada, Janssen, Lundbeck, Lundbeck Institute, Michael Smith Foundation for Health Research, MITACS, Myriad Neuroscience, Ontario Brain Institute, Otsuka, Pfizer, Unity Health, and VGH-UBCH Foundation.
Funding Statement
This study was funded by the Michael Smith Foundation for Health Research, award P2P18925. IL was funded by a Mach-Gaensslen Foundation of Canada Award from the UBC Faculty of Medicine Summer Student Research Program.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This online survey study received approval from the Behavioural Research Ethics Board at the University of British Columbia.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon request.
